12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

Advancell, Helsinn deal

Advancell granted Helsinn exclusive, worldwide rights to develop and commercialize ATH008. The undisclosed topical cream is in development to treat palmoplantar erythrodysesthesia...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >